Effects of lung cancer treatments on muscle mass and physical performance
Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.
This study is trying to see how different treatments for advanced lung cancer affect muscle mass and physical ability in patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 240 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Prince of Songkla University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 1 site (Hat Yai, Songkla) |
| Trial ID | NCT06326086 on ClinicalTrials.gov |
What this trial studies
This observational study investigates how different treatments for advanced non-small cell lung cancer (NSCLC), including chemotherapy, targeted therapy, and immunotherapy, impact skeletal muscle mass and physical performance in patients. It aims to assess the decline in muscle mass and physical capabilities before and after treatment, as these factors are linked to overall survival and prognosis. The study will involve patients aged over 18 with advanced NSCLC, focusing on the relationship between treatment modalities and sarcopenia, a condition characterized by muscle loss. By analyzing these effects, the research seeks to provide insights into improving patient outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with stage IIIB, IIIC, or IV non-small cell lung cancer who are undergoing chemotherapy, targeted therapy, or immunotherapy.
Not a fit: Patients with physical disabilities that prevent them from participating in assessments or those with other primary malignancies may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better management strategies for preserving muscle mass and physical performance in lung cancer patients, potentially improving their survival rates.
How similar studies have performed: While some studies have indicated a decline in muscle mass during chemotherapy in lung cancer patients, data on the effects of targeted therapy and immunotherapy on muscle mass are limited, making this approach relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \>18years old, 2. Stage IIIB and IIIC (if patients are treated with TKI/IO), and Stage IV non-small cell lung cancer patients confirmed by histopathology. 3. Patients should be either on chemotherapy, molecular targeted therapy or immunotherapy. Exclusion Criteria: 1. Unable to perform CT scan due to various reasons. 2. Patients with metastatic disease at L3 vertebral level. 3. If unable to perform SPPB test due to physical disability or patient's refusal. 4. Patients with known other primary malignancies. 5 . Patients who have underwent definitive surgery. 6. Pregnant patients. 7. Patients with physical deformities/neurological deficits which restricts their physical movements.
Where this trial is running
Hat Yai, Songkla
- Prince of Songkla University — Hat Yai, Songkla, Thailand (Recruiting)
Study contacts
- Study coordinator: Shiva R Timsina, MBBS
- Email: timsinasraj@gmail.com
- Phone: +660623898980
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.